Clinical trial / 2012
Curcumin dose may affect light-chain response and bone turnover in MGUS and SMM.
In a randomized, double-blind crossover study with 36 patients, participants received a 4g dose of curcumin or placebo for 3 months before crossing over, followed by an optional 8g open-label extension. Curcumin treatment decreased the free light-chain ratio and reduced the difference between clonal and nonclonal light chains. Urine DPYD, representing bone resorption, decreased with curcumin but rose with placebo, while serum creatinine tended to drop.
- Study type
- Randomized double-blind crossover trial and open-label extension
- Who was studied
- 36 patients with MGUS or SMM
- What was measured
- Free light-chain response, bone turnover markers, and serum creatinine
THE PAPER
Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study.
Golombick T, Diamond TH, Manoharan A, Ramakrishna R. Am J Hematol, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.